What do systematic reviews say?

Renin‐angiotensin system inhibition vs supportive treatment

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 168 participants
  Moderate

Renin‐angiotensin system inhibition vs placebo or no treatment

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 199 participants
  Moderate

Renin‐angiotensin system inhibition vs supportive treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs supportive treatment

The review found no eligible studies for this question.

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Renin‐angiotensin system inhibition vs placebo or no treatment

Renin‐angiotensin system inhibition showed no clear difference in remission of proteinuria: complete remission compared with placebo or no treatment (low certainty).

• Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
  RR 5.29 [0.27, 102.49]
  1 study · 33 participants
  Low

Aldosterone antagonists vs diuretics

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 139 participants
  Very low

Aldosterone antagonists vs calcium channel blockers

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Aldosterone antagonists vs ACEi or ACEi plus ARB

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 465 participants
  Very low

Aldosterone antagonists vs nitrate

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Low

Non‐steroidal mineralocorticoid receptor antagonist vs selective aldosterone antagonist

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  14 studies · 1193 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo/no treatment

• Antihypertensive treatment for kidney transplant recipients 2009 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 175 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs calcium channel blockers

• Antihypertensive treatment for kidney transplant recipients 2009 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 142 participants
  Moderate

Calcium channel blockers vs placebo/no treatment

• Antihypertensive treatment for kidney transplant recipients 2009 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 90 participants
  Low